Related references
Note: Only part of the references are listed.An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Faruque Ghanchi et al.
EYE (2022)
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Jeffrey S. Heier et al.
LANCET (2022)
Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions
Paolo Corazza et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2022)
Retinal vein occlusion (RVO) guideline: executive summary
Luke Nicholson et al.
EYE (2022)
Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
Debdulal Chakraborty et al.
CASE REPORTS IN OPHTHALMOLOGY (2022)
Markedly decreasing incidence of cause-specific blindness in Saxony (Eastern Germany)
Heiner Claessen et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)
Modelling and prognostication of growth in the number of patients treated for neovascular age-related macular degeneration
Ivan Potapenko et al.
ACTA OPHTHALMOLOGICA (2021)
Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study
Rupert R. A. Bourne et al.
LANCET GLOBAL HEALTH (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Neovascular Age-Related Macular Degeneration in the Very Old (>= 90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy
Yousif Subhi et al.
JOURNAL OF OPHTHALMOLOGY (2017)
Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years
Sandra Rezar et al.
ACTA OPHTHALMOLOGICA (2015)
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion The 24-Week Results of the VIBRANT Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2015)
A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration
Annette Rasmussen et al.
OPHTHALMOLOGY (2013)
Time Trends in the Incidence and Causes of Blindness in Israel
Alon Skaat et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Sara Brandi Bloch et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2010)
Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities
Jiri Rehak et al.
CURRENT EYE RESEARCH (2008)